Vycor Medical Inc. Reports 24% Revenue Increase and Break-Even EPS for <a href="https://laohu8.com/S/QTWO">Q2</a> 2025, Achieves $23,887 Net Income
Vycor Medical Inc. has reported its financial results for the three and six months ending June 30, 2025. The company experienced a notable increase in revenue, with the Vycor Medical division seeing a 24% rise in revenue for the three-month period and a 28% increase for the six-month period, primarily driven by growth in international markets. For the three months ended June 30, 2025, Vycor Medical reported revenue of $496,353, up from $406,278 in the same period of 2024. The gross profit for the same period rose to $415,271 from $371,115. For the six months ended June 30, 2025, revenue increased to $932,731 compared to $743,246 in the prior year, with gross profit rising to $773,805 from $671,077. The company posted a GAAP net income of $23,887 for the three-month period, with an operating profit of $51,146. Vycor Medical's non-GAAP operating profit for the same period was $84,481, reflecting a significant increase over the 2024 periods. Vycor Medical has also expanded its international presence by entering into new distribution agreements for France and Spain during the first half of 2025, identifying these as key markets for further international expansion. No specific outlook or guidance was provided in the release.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on August 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.